Collegium Pharmaceutical Stock Today
| COLL Stock | USD 30.05 0.12 0.40% |
PerformanceWeak
| Odds Of DistressBelow Average
|
Collegium Pharmaceutical is selling for 30.05 as of the 23rd of March 2025. This is a 0.40 percent increase since the beginning of the trading day. The stock's lowest day price was 29.25. Collegium Pharmaceutical has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of May 2015 | Category Healthcare | Classification Health Care |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Collegium Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 31.49 M outstanding shares of which 5.21 M shares are currently shorted by private and institutional investors with about 16.56 trading days to cover. More on Collegium Pharmaceutical
Moving against Collegium Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Collegium Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Vikram Karnani | ||||
| Old Name | Collector AB (publ) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, OMX Stockholm Mid, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCollegium Pharmaceutical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Collegium Pharmaceutical's financial leverage. It provides some insight into what part of Collegium Pharmaceutical's total assets is financed by creditors.
| |||||
Collegium Pharmaceutical (COLL) is traded on NASDAQ Exchange in USA. It is located in 100 Technology Center Drive, Stoughton, MA, United States, 02072 and employs 357 people. Collegium Pharmaceutical is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 946.14 M. Collegium Pharmaceutical conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 31.49 M outstanding shares of which 5.21 M shares are currently shorted by private and institutional investors with about 16.56 trading days to cover.
Collegium Pharmaceutical currently holds about 122.72 M in cash with 204.98 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.6.
Check Collegium Pharmaceutical Probability Of Bankruptcy
Ownership AllocationCollegium Pharmaceutical holds a total of 31.49 Million outstanding shares. Almost 86.07 percent of Collegium Pharmaceutical outstanding shares are held by general public with 1.93 (percent) owned by insiders and only 12.0 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Collegium Ownership Details
Collegium Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Emerald Advisers, Llc | 2024-12-31 | 811.7 K | |
| Geode Capital Management, Llc | 2024-12-31 | 770.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 679.3 K | |
| Massachusetts Financial Services Company | 2024-12-31 | 604.2 K | |
| Emerald Mutual Fund Advisers Trust | 2024-12-31 | 569.6 K | |
| Victory Capital Management Inc. | 2024-12-31 | 559.5 K | |
| Lsv Asset Management | 2024-12-31 | 390.5 K | |
| Northern Trust Corp | 2024-12-31 | 385.2 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 367.4 K | |
| Blackrock Inc | 2024-12-31 | 5.6 M | |
| Eventide Asset Management, Llc | 2024-12-31 | 2.6 M |
Collegium Pharmaceutical Historical Income Statement
Collegium Stock Against Markets
Collegium Pharmaceutical Corporate Management
| Shirley JD | General VP | Profile | |
| Bart Dunn | Executive Development | Profile | |
| Scott Sudduth | Head Operations | Profile | |
| Christopher MD | Vice Relations | Profile | |
| Marlo Manning | Head HR | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 1.86 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.